Shots:
- Lipocine to receive $11.0M up front, $5.0M as licensing fees in Jan’25 & $5.0M in Jan’26, ~$160.0M as sales-based commercial milestone based on Tlando net sales, if Antares exercises Tlando XR option & royalties on sales of Tlando
- Antares to get an option to license Tlando XR for TRT in the US on or before March 31, 2022. Upon exercise of Tlando XR option, Lipocine to receive $4.0M as license fees, clinical & regulatory milestone of ~$35.0M along with royalties
- Antares will lead all commercialization, post-marketing obligations & sourcing of Tlando in the US along with Tlando XR. Lipocine holds all rights for Ex-US territories & non-TRT indications for Tlando & Tlando XR
Click here to read the full press release/ article | Ref: PR Newswire | Image: PR Newswire
The post Lipocine Enters into an Exclusive License Agreement with Antares to Commercialize Tlando in the US first appeared on PharmaShots.
